HENDERSON, Nev., Jan. 4, 2024 /PRNewswire/ -- VolitionRx Limited (VNRX) ("Volition"), a multi-national epigenetics company, has issued a Business Review of 2023, outlining its key highlights from the ...
Cameron Reynolds, President and Group Chief Executive Officer, said: "As we head into 2025, Volition is at a pivotal juncture, ready to revolutionize the diagnosis and monitoring of life-altering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback